BIRD-C

Werner Lubitz, PhD
Chief Executive Officer (CEO) and Chief Scientific Officer (CSO)

 

Prof. Dr. Werner Lubitz holds an MSc and a PhD in Microbiology and Genetics from the Technical University of Munich, Germany. He obtained his postdoctoral training at the Universities of Lausanne and Basel, Switzerland; Uppsala, Sweden; Victoria, Canada and at the Max Planck Institute for Psychiatry, Munich, Germany. Dr. Lubitz was an Associate Professor of Microbiology at the University of Kaiserslautern, Germany and Associate Professor of Genetics at the University of Munich, Germany. Since 1987, he has been a Full Professor at the University of Vienna, Austria, first at the Institute of Microbiology and Genetics, and recently at the Department of Medicinal Chemistry. Werner Lubitz has published more than 100 papers in internationally peer-reviewed journals. As inventor of the Bacterial Ghost Platform Technology he holds an extensive international patent portfolio. In 1998, Dr. Lubitz founded the biotech company BIRD-C in Vienna.

 

 

 

Petra Lubitz, PhD
Chief Operating Officer (COO), Head of Vaccine Development

 

Petra Lubitz holds an MSc and PhD in Microbiology and Genetics from the University of Vienna, Austria. For her PhD thesis, she worked for several months at Landcare Research Ltd. in New Zealand on the development of an oral immunocontraceptive vaccine for the possum, New Zealand’s most noted pest animal. During her scientific activities she worked in Australia, New Zealand, USA and Austria. In 2004, Petra Lubitz joined BIRD-C as Project Coordinator. Since 2006, she has been responsible for managing the company’s day-to-day business activities. Furthermore, she is working as Divisional Head of Vaccine Development.

 

 

 

 

 

Last update: waiting for actual data ...